Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
AXSMthis companyAxsome Therapeutics, Inc.	$133.82	-49.63×	102.9×	14.23×	-53.57×	-423.3%	92.6%	-26.5%	-28.7%	-207.5%	-44.0%	-1.0%	2.73×	0.49×	-25.81×	1.55×	0.0%	3	4.25	1	D+
AVXLAnavex Life Sciences Corp.	$1.19	-16.48×	8×	0×	-14.16×	2.3%	0.0%	0.0%	0.0%	-48.9%	-54.2%	-5.1%	0×	2.21×	0×	11.6×	0.0%	1	4.27	2	C
DFTXDefinium Therapeutics, Inc.	$34.59	-6.5×	3.6×	0×	-5.26×	-91.2%	0.0%	0.0%	0.0%	-55.3%	-44.5%	-11.0%	0×	1.45×	-30.34×	6.29×	0.0%	3	12.28	2	C
DNLIDenali Therapeutics Inc.	$20.23	-5.56×	2.86×	0×	-5.48×	-94.9%	0.0%	0.0%	0.0%	-50.6%	-52.6%	-14.6%	0.04×	0.34×	0×	9.16×	0.0%	3	2.05	2	C
NBIXNeurocrine Biosciences, Inc.	$165.00	29.49×	4.34×	4.93×	20.72×	140.9%	98.2%	21.6%	16.7%	14.7%	10.8%	5.3%	0.13×	-0.45×	0×	3.39×	0.0%	5	6.69	4	A
NMRANeumora Therapeutics, Inc. Common Stock	$0.54	-1.23×	2.82×	0×	-0.47×	121.4%	0.0%	0.0%	0.0%	-228.1%	-151.8%	-70.6%	0×	0.78×	-74.92×	5.87×	0.0%	2	-18.15	2	C+
Peer median	—	-5.56×	3.6×	0×	-5.26×	2.3%	0.0%	0.0%	0.0%	-50.6%	-52.6%	-11.0%	0×	0.78×	0×	6.29×	0.0%	3	4.27	2	—